Drug Profile
TQ B3139
Alternative Names: TQ-B3139Latest Information Update: 29 Sep 2022
Price :
$50
*
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase I Solid tumours
Most Recent Events
- 28 Sep 2022 TQ B3139 is still in phase II trial for Non-small cell lung cancer (In adults, Late-stage disease, Second-line therapy or greater) in China (PO) (NCT04398940)
- 23 Feb 2022 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (PO) (NCT04675060)
- 19 Dec 2020 Chia Tai Tianqing Pharmaceutical Group plans a phase I trial for Solid tumours (Late-stage disease) in China (PO) in December 2020 (NCT04675060)